BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023
March 27, 2023 07:00 ET
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...
BiomX Announces $7.5 Million Private Placement
February 22, 2023 06:35 ET
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...
BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
February 22, 2023 06:30 ET
|
BiomX
BX004 therapy safe and well-tolerated across all patients and dose levels Preliminary signals of efficacy also observed, with notable reductions in bacterial burden Dosing in patients in Part 2...
BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
November 29, 2022 09:10 ET
|
BiomX
NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage...
BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022 06:30 ET
|
BiomX
Continued Progress Enrolling Patients in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis; Results from Part 1 of the Trial Now Expected in Q1 2023 Announced Publication...
BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
November 02, 2022 09:00 ET
|
BiomX
NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage...
BiomX Presenting at Two Upcoming Conferences in November
November 17, 2021 08:00 ET
|
BiomX
Jefferies London Healthcare Conference on November 18 - 19, 2021 2021 Phage Futures Congress Europe on November 23 - 24, 2021 NESS ZIONA, Israel, Nov. 17, 2021 (GLOBE NEWSWIRE) --...
BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update
November 15, 2021 06:00 ET
|
BiomX
Announces Strategic Focus on Cystic Fibrosis and Atopic Dermatitis Programs Based on Potential Proof-of-Concept Clinical Data Readouts in 2022 Cash Runway Now Extended to End of 2023, Well Beyond Key...
BiomX to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 15, 2021
November 09, 2021 08:00 ET
|
BiomX
NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage...
BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study
October 18, 2021 07:00 ET
|
BiomX
12-Week Study of BX001 Meets Safety and Tolerability Endpoints Statistically Significant Improvement from Baseline Observed in Appearance of Acne-prone Skin but No Meaningful Difference Demonstrated...